RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
Public ClinicalTrials.gov record NCT04832724. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered Via Subretinal Delivery in Participants With Neovascular Age-related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD. Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. The purpose of this phase 2, open label study is to evaluate whether different doses of RGX-314 from two different formulations (clinical versus eventual commercial formulation) perform the same in humans when delivered by subretinal administration
Study identification
- NCT ID
- NCT04832724
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2021 (Actual)
- Primary completion
- Oct 2, 2023 (Actual)
- Completion
- Mar 18, 2024 (Actual)
- Last update posted
- Sep 5, 2024
2021 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retinal Consultants of Arizona | Phoenix | Arizona | 85014 | — |
| Barnet Dulaney Perkins Eye Center | Sun City | Arizona | 85351 | — |
| Retina Consultants of San Diego | San Diego | California | 92064 | — |
| California Retina Consultants | Santa Barbara | California | 93103 | — |
| Retina Vitreous Associates of Florida | St. Petersburg | Florida | 33711 | — |
| Wilmer Eye Institute | Baltimore | Maryland | 21287 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| Eye Associates of New Mexico | Albuquerque | New Mexico | 87109 | — |
| Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Charles Retina Institute | Germantown | Tennessee | 38138 | — |
| Texas Retina Associates | Dallas | Texas | 75231 | — |
| Retina Consultants of Texas | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04832724, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 5, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04832724 live on ClinicalTrials.gov.